Surrogate end points in critical illness research: Some way to go yet

Critical Care Medicine

Volumn 39, Issue 11, 2011, Pages 2561-2562

  Ioannou, Nicholas ^a   Terblanche, Marius ^b,c  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

acid base; critical care; hyperchloremia; intensive care unit; metabolic acidosis; outcome; surrogate end points

Indexed keywords

ACID BASE BALANCE; CRITICAL ILLNESS; EDITORIAL; HUMAN; MEDICAL RESEARCH; METABOLIC DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

CHLORIDES; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; PLASMA SUBSTITUTES; SOLUTIONS;

EID: 80054929360     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822a581a     Document Type: Editorial

References (15)

1. Smith I, Kumar P, Molloy S, et al: Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med 2001; 27:74-83 (Pubitemid 32208972)
2. Gunnerson KJ, Saul M, He S, et al: Lactate versus non-lactate metabolic acidosis: A retrospective outcome evaluation of critically ill patients. Crit Care 2006; 10:R22
3. Prough DS, Bidani A: Hyperchloremic acidosis is a predictable consequence of intraoperative infusion of 0.9% saline. Anaesthesiology 1999; 90:1247-1249 (Pubitemid 29205623)
4. Kellum JA: Saline-induced hyperchloraemic metabolic acidosis. Crit Care Med 2002; 30:259-261
5. Skellett S, Mayer A, Durward A, et al: Chasing the base deficit: Hyperchloraemic acidosis following 0.9% saline fluid resuscitation. Arch Dis Child 2000; 83:514-516
6. Morgan TJ: The meaning of acid-base abnormalities in the intensive care unit: Part III-Effects of fluid administration. Crit Care 2005; 9:204-211 (Pubitemid 40425447)
7. Yunos NM, Kim IB, Bellomo R, et al: The biochemical effects of restricting chloriderich fluids in intensive care. Crit Care Med 2011; 39:2419-2424
8. Bucher HC, Guyatt GH, Cook DJ, et al: Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints. JAMA 1999; 282:771-778 (Pubitemid 29404385)
9. Temple RJ: A regulatory authority's opinion about surrogate endpoints. In: Clinical Measurement in Drug Evaluation. Nimmo WS, Tucker GT (Eds). New York, John Wiley & Sons Inc, 1995, p 57
10. Bakker J, Grover R, McLuckie A, et al: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebocontrolled multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12 (Pubitemid 38125557)
11. López A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30 (Pubitemid 38125559)
12. Friedrich JO, Adhikari N, Herridge MS, et al: Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510-524
13. Afshari A, Brok J, Møller AM, et al: Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010; 7:CD002787
14. Sackner-Bernstein JD, Kowalski M, Fox M, et al: Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-1905 (Pubitemid 40548187)
15. Fleming TR, DeMets DL: Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125:605-613 (Pubitemid 126450094)